VBIV
VBI Vaccines Inc
Price:  
0.07 
USD
Volume:  
29,900,212.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

VBIV WACC - Weighted Average Cost of Capital

The WACC of VBI Vaccines Inc (VBIV) is 8.4%.

The Cost of Equity of VBI Vaccines Inc (VBIV) is 29.05%.
The Cost of Debt of VBI Vaccines Inc (VBIV) is 9.40%.

Range Selected
Cost of equity 12.50% - 45.60% 29.05%
Tax rate 26.20% - 27.00% 26.60%
Cost of debt 7.00% - 11.80% 9.40%
WACC 5.7% - 11.2% 8.4%
WACC

VBIV WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 1.88 7.28
Additional risk adjustments 0.0% 0.5%
Cost of equity 12.50% 45.60%
Tax rate 26.20% 27.00%
Debt/Equity ratio 13.32 13.32
Cost of debt 7.00% 11.80%
After-tax WACC 5.7% 11.2%
Selected WACC 8.4%

VBIV's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for VBIV:

cost_of_equity (29.05%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (1.88) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.